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Introduction. The IOERT is a variety of treatment that consists of direct and precise irradiation of a tumor bed during the surgical
act. This allowsdirect visualization of target volumes,with the consistent reduction of toxicity in adjacent healthy tissues through
their separation. The major recurrences can be found in the immediate vicinity of the tumor bed (85% in the same quadrant).
Aim. Evaluation of surgical complications, acute and aesthetic toxicity in patients with breast cancer and IOERT.
Materials and methods. Between July 2008 and January 2013, 21 women previously diagnosed with breast cancer, have been treated
with conservative surgery: mean age 65 (39–82). Inclusion criteria: PS 0–1, age≥45 years, histology of inﬁltrating single centered
ductal carcinoma; tumor size≤2.5 cm, no surgical macroscopically negative margins and study prior to surgery with mammog-
raphy and magnetic resonance. IOERT was administered in 7 patients (33.3%) as a boost (9Gy), and as exclusive (21Gy) in 14
(66.7%), including the PTV+2cm margin. The applicator most used was 6 and 7 cm (35%) and energy of 9MeV (65%). External
radiotherapy consisted of 40.05–50Gy. Acute toxicity was assessed with the RTOG scale.
Results. The follow up was 53 months. Two patients developed postoperative seroma requiring drainage. The acute toxicity was
G1 in 14 (71.4%) and G2 in 6 (28.6%). The aesthetics was good or excellent in 80% and 20% acceptable.
Conclusions. The IOERT can be used as exclusive treatment or prior to external radiotherapy as an overlay. Eliminates the possible
vagueness of the tumor location, allowing treatment with a limited volume of glandular tissue. By preserving the skin and
subcutaneous tissue of radiation reduces the likelihood of ﬁbrosis and telangiectasia, which improves aesthetics and toxicity. It
also reduces the duration of radiation contributing to patient’s comfort and cost reduction.
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Background and purpose. To evaluate local control, early and late reactions and disease-free survival of elderly breast cancer
patients treated with adjuvant or deﬁnitive once-a-week hypofractionated (HF) radiotherapy (RT).
Patients and methods. Between 2007 and 2012, 107 patients with a median aged 78.03 (35–89) years with breast cancer were treated
by breast-conserving surgery or radical surgery and adjuvant Radiotherapy. The main reasons for adopting this schedule were
patient very old age, locally advanced case, and/or comorbid disease. Radiation was delivered as once-a-week, 6.5Gy for a total
breast dose of 32.5Gy in ﬁve fractions, followed with 1–2 fractions of 6.5Gy to the tumour site.
Results. There was a median follow-up of 30.30 months (6.9–58.8 months). 88 (82.2%) patients underwent breast-conserving
surgery (BCS), 14 (13.1%) patients radical surgery and 5 (4.1%) no surgery. The clinical stage distribution was as follows: T1 in
49.2%, T2 in 35.8%, T3 in 9.4%, and T4 in 5.6%. Axillary lymph nodes were positive in 59% of cases. Estrogen receptors were
present in 85.7%, and progesterone receptors in 85.6%. Human epidermal growth factor receptor-2-positive (HER-2+) in 8.2% of
case. Early skin reactions were tolerable with no documented Radiation Therapy Oncology Group Grade 3 or higher toxicity. Late
effects, mainly subcutaneous ﬁbrosis, were recorded in 54 patients, they were classiﬁed as grade 1 in 41 cases, grade 2 in 8 cases
and grade 3 in 5 patients. No toxicity in 51 patients. Local and distant failure was scored in 9 cases (8,6%). At a median follow-up
of 30.30 months (6.9–58.8 months), 81 patients (75.7%), was alive and disease free.
Conclusions. According to the ﬁndings from this retrospective study, the HF-RT schedule is an acceptable alternative for elderly
patients, allows a good local control, with acceptable toxicity.
http://dx.doi.org/10.1016/j.rpor.2013.03.727
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Purpose. Concerns with the use of any form of APBI relate to the large fraction sizes administered and a possible increase in
the rate of development of late effects. We analyzed toxicity and cosmetics results using three-dimensional conformal external
beam radiation therapy (3D-CRT) to deliver accelerated partial breast irradiation in our phase III trial.
Methods and materials. One hundred and two patients undergoing breast-conserving surgery were randomized to receive WBRT
(n=51) or APBI (n=51). The whole breast received 48Gy with 2-Gy daily fractions, with or without additional 10Gy irradiation to
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the tumor bed, depending on local recurrence risk factors. In APBI arm, patients received 37.5Gy in 3.75Gy/fraction delivered
twice daily. Toxicity results were scored based on the RTOG Common Toxicity Criteria. Late skin toxicity was measured by
Multi-Skin-Center® MC-750-B2, CKelectronic-GmbH, which allow the users to put together measuring parameters for the skin:
pigmentation (melanin), redness (erythema), TEWL (transepidermal waterloss index) and elasticity. Cosmetic results were rated
as good/excellent, regular or poor cosmetic result by the treating radiation oncologist and every patient.
Results. With a median follow-up of 5 years, no local recurrences were developed. Acute skin effects were noted in 46/51 patients
of APBI arm (72.5% grade I and 17.6% grade II) and in all patients of control arm (25.5% grade I, 62.7% grade II and 11.8% grade
III). Only one case of grade II acute pneumonitis was noted and it was in one woman of the WBRT arm. Only grades I and II late
effects were reported. There was a slight increase of grade I toxicity up to 3 years in APBI arm. At 4 years, late skin toxicity was
similar between WBRT and APBI arm (16 vs 11% grade I, respectively and no grade II toxicity was reported). Elasticity was lower
in highest doses area (boost or quadrant) than in ipsilateral breast. Taking into account only this area, elasticity was lower in
WBRT arm than in APBI arm.
Conclusions. Delivery of APBI with 3D-CRT resulted in minimal chronic (>6 months) toxicity to date with good/excellent cosmetic
results. Additional follow-up is needed to assess the long-term efﬁcacy of this form of APBI. Therefore, this noninvasive approach
may increase the availability of APBI to patients with early-stage breast cancer.
http://dx.doi.org/10.1016/j.rpor.2013.03.728
